Differential response to intravenous XXXX analog therapy in @entity1 with @entity120 .

@entity1 @entity712 @entity120 @entity4770 @entity13992 @entity785
BACKGROUND: @entity13992 is an intravenous @entity4770 analog approved for the treatment of @entity120 ( @entity120 ). Few studies have compared the pharmacodynamics and effectiveness of @entity13992 and @entity4770 in @entity1 with high-risk @entity120 . METHODS: Case series of @entity1 with @entity120 admitted to a Medical Intensive Care Unit for transition from @entity4770 to intravenous @entity13992 for refractory class III-IV functional symptoms or @entity712 . Mixed linear models were used for comparisons between repeated hemodynamic measurements. RESULTS: Five of fourteen @entity1 treated with intravenous @entity13992 during the study period underwent transition to @entity4770 . Two had @entity120 associated with @entity785 , three had idiopathic @entity120 . Pulmonary arterial pressures (PAP) and pulmonary vascular resistance significantly increased within 1 h after discontinuation of @entity13992 in all subjects. Mean PAPs immediately prior to discontinuation of @entity13992 (53.4    7.5 mmHg) were significantly lower than the values 1 h after discontinuation (63.6    9.6 mmHg, p = 0.026), but were significantly higher than the values following transition to @entity4770 (45.4    5.5, p = 0.0493); 4/5 subjects had short-term clinical follow-up data available; all improved in functional class. No subject experienced adverse events during the transition. CONCLUSIONS: High-risk @entity120 @entity1 with an inadequate response to @entity13992 may have significant clinical and hemodynamic response to @entity4770 . Following discontinuation of @entity13992 in these @entity1 , the hemodynamic effects of discontinuation were seen in substantially shorter time than what is known to be the pharmacokinetic terminal half-life.
